Dr. Poligone is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
6800 Pittsford Palmyra Rd
Ste 150
Fairport, NY 14450Phone+1 585-364-1177Fax+1 585-461-3509
Education & Training
Yale-New Haven Medical CenterResidency, Dermatology, 2004 - 2007
Stanford Health Care-Sponsored Stanford UniversityInternship, Internal Medicine, 2003 - 2004
University of North Carolina at Chapel Hill School of MedicineClass of 2003
Certifications & Licensure
NY State Medical License 2008 - 2025
CT State Medical License 2007 - 2008
American Board of Dermatology Dermatology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
- Fellow (FAAD) American Academy of Dermatology
Clinical Trials
- Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL) Start of enrollment: 2010 Jan 06
- Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL Start of enrollment: 2012 Nov 01
- Mechlorethamine Induced Contact Dermatitis Avoidance Study Start of enrollment: 2017 Dec 13
Publications & Presentations
PubMed
- Lysophosphatidic acid down-regulates human RIPK4 mRNA in keratinocyte- derived cell lines.Lei Xu, Peter Bajorski, Brian Poligone
Plos One. 2024-01-01 - 20 citationsEfficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial.Ellen J Kim, Aaron R Mangold, Jennifer A DeSimone, Henry K Wong, Lucia Seminario-Vidal
JAMA Dermatology. 2022-09-01 - 4 citationsLong-term disease control and safety with the anti-CCR4 antibody mogamulizumab: Post-hoc analyses from the MAVORIC trial of patients with previously treated cutaneous ...Martine Bagot, Stéphane Dalle, Lubomir Sokol, Athansios Tsianakas, Amy Musiek
Dermatologic Therapy. 2022-08-01
Press Mentions
HyBryte™ Expanded Treatment Results to Be Presented at the European Organisation for Research and Treatment of Cancer ConferenceOctober 7th, 2024- Soligenix Corporate Update Letter - Key Highlights and Upcoming CatalystsJanuary 10th, 2022
- Soligenix Anticipated to Achieve Multiple Milestones in 2021March 16th, 2021
- Join now to see all
Grant Support
- NF Kappa B Activity In Skin Inflammation And CarcinogenesisNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2009–2011
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
